gamma-aminobutyric acid and Hyperemesis Gravidarum studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Hyperemesis Gravidarum: Intractable VOMITING that develops in early PREGNANCY and persists. This can lead to DEHYDRATION and WEIGHT LOSS.

Research Excerpts

Excerpt	Relevance	Reference
" Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)."	8.90	Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014)
"Among 7 subjects with hyperemesis gravidarum (HG), we found gabapentin therapy to be associated with mean reductions in nausea and emesis from Baseline to Days 12-14 of 80% and 94%, respectively."	7.76	Gabapentin use in hyperemesis gravidarum: a pilot study. ( Amankwah, KS; Guttuso, T; Robinson, LK, 2010)
" If future pregnancy registry data confirm this positive safety profile, gabapentin therapy would likely be a safe and effective treatment for RLS during pregnancy."	6.50	Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014)
" Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)."	4.90	Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014)
"Among 7 subjects with hyperemesis gravidarum (HG), we found gabapentin therapy to be associated with mean reductions in nausea and emesis from Baseline to Days 12-14 of 80% and 94%, respectively."	3.76	Gabapentin use in hyperemesis gravidarum: a pilot study. ( Amankwah, KS; Guttuso, T; Robinson, LK, 2010)
" If future pregnancy registry data confirm this positive safety profile, gabapentin therapy would likely be a safe and effective treatment for RLS during pregnancy."	2.50	Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014)

Research

Studies (2)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Narcotic Utilization

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Guttuso, T	2
Shaman, M	1
Thornburg, LL	1
Robinson, LK	1
Amankwah, KS	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
"Determining the Effect of an Alternate Recovery Protocol Versus Current Standard of Care After Cesarean Section"[NCT03330119]	Phase 3	1,494 participants (Actual)	Interventional	2017-10-04	Terminated (stopped due to Lack of Funding/ Resident in charge graduated)
Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum[NCT02163434]	Phase 2	31 participants (Actual)	Interventional	2014-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"total narcotic utilization measured with Morphine Milligram Equivalent (MME)~The conversion scale being used will be the Center for Disease Control and Prevention Morphine Equivalent Score.~Lower scores represent less opioid use and a better outcome. Higher scores represent more opioid use and a worse outcome." (NCT03330119)
Timeframe: From time of consent until hospital discharge (3 days)

Baseline Adjusted Mean Daily Motherisk-PUQE Total Scores (Pregnancy-unique Quantification of Emesis and Nausea Scale) for Days 5-7

Intervention	MME (Mean)
Alternate Management	33.3
Control	47.2

Score range: 6-30 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week

Baseline Adjusted Mean Daily Nausea Scores From the Motherisk-PUQE for Days 5-7.

Intervention	units on a scale (Mean)
Gabapentin	6.35
Metoclopramide	13.22

Score range: 2-10 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week

Baseline Adjusted Mean Daily Oral Nutrition Score for Days 5-7

Intervention	units on a scale (Mean)
Gabapentin	2.01
Metoclopramide	3.69

Score range: 0-15 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week

Desire to Continue Therapy at Study Endpoint

Intervention	units on a scale (Mean)
Gabapentin	7.86
Metoclopramide	4.01

Scores: 0=no, 1=yes. Thus, a higher score indicates a better outcome. (NCT02163434)
Timeframe: 1 week

Global Satisfaction of Treatment at the Study Endpoint.

Intervention	units on a scale (Mean)
Gabapentin	0.67
Metoclopramide	0.14

Score range: 0-4 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week

gamma-aminobutyric acid and Hyperemesis Gravidarum